問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chung Shan Medical University Hospital (在職)

Division of General Internal Medicine

Division of Hematology & Oncology

Division of Thoracic Medicine

更新時間：2023-09-19

曲承鑲
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

23Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

曲承鑲

List

32Cases

2025-02-01 - 2030-12-31

Active
A Phase 3 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 Compared to Alectinib in First-Line Treatment of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer (ALKAZAR)

  • Condition/Disease

    Non-small Cell Lung Cancer 、Anaplastic Lymphoma Kinase-positive

  • Test Drug

    Tablets; Hard capsules

Participate Sites
4Sites

Recruiting4Sites

2024-06-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting6Sites

2025-08-01 - 2031-12-31

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2023-04-01 - 2025-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Terminated1Sites

2023-02-23 - 2026-10-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting3Sites

2026-01-01 - 2028-01-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

2021-11-01 - 2026-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Not yet recruiting6Sites

Recruiting1Sites

2022-08-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2020-11-01 - 2027-06-30

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2024-10-01 - 2029-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

1 2 3 4
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB